Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FABP6 | P51161 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8506510 | 0.86 | HPGD (0.45) | MAPK1ALDH1A1HPGD | |
| SCHEMBL31106410 | 0.86 | HPGD (0.45) | MAPK1ALDH1A1HPGD | |
| SCHEMBL5966136 | 0.76 | CES2 (0.38) | ALDH1A1HPGD | |
| SCHEMBL31106414 | 0.74 | CYP3A4 (0.47) | GAAMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31106403 | 0.74 | CYP3A4 (0.47) | GAAMAPK1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29457007 | 0.70 | PKM (0.66) | MAPK1ALDH1A1POLBTDP1HPGD | |
| SCHEMBL6640482 | 0.70 | PKM (0.66) | MAPK1ALDH1A1POLBTDP1HPGD | |
| SCHEMBL5966095 | 0.70 | FKBP1A (0.52) | CHRM2ALDH1A1 | |
| SCHEMBL5966058 | 0.69 | CES2 (0.40) | — | |
| SCHEMBL15560427 | 0.69 | TSHR (0.46) | GAAALDH1A1POLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361253-A1 | COMPOUNDS | Selcia Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20110184011-A1 | Compounds | SELCIA LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| WO-2010029364-A1 | COMPOUNDS | SELCIA LIMITED (GB) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184011-A1 | Compounds | COL1A1, ALDH1A2, COL2A1 | CHRM2 178/4885GAA 3174/4885MAPK1 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.